Search results for "protein l"
Article
mAbs to Watch in 2016
By Randi Hernandez
Of the 45 new molecular entities and new therapeutic biological products approved by FDA in 2015, nine products were monoclonal antibodies (mAbs). And there may be many more o…
Article
SEC in the Modern Downstream Purification Process
Mar 01, 2015
By R. Christopher Manzari, J. Kevin O'Donnell
BioPharm International
Volume 3, Issue 28
Since the introduction of commercial chromatography resins approximately six de…
Article
Improving PAT for Biologics
The complexity of biopharma processes requires innovative solutions.
Dec 01, 2014
By Cynthia Challener, PhD
BioPharm International
A key component of the quality-by-design (QbD) ap…
Article
High-Throughput Process Development in an Historical Environment
Presentations, discussions, and information-sharing on modern bioprocess technology and high-throughput process development (HTPD) in an historical and culturally enriched environment is the essence…
Article
Buffer optimization for separation of bsAb in a capture step using MabSelect™ VL resin
…dimers for bsAb’s, and removal of light chain from mAbs during elution when using MabSelect™ VL protein L resin. The video includes results of these experiments and a discussion of how buffer screeni…
Article
Fundamentals of hydrophobic interaction chromatography
Hydrophobic interaction chromatography (HIC) is a versatile technique that can be used for capture, intermediate purification, or polishing steps.
This technique separates proteins accor…
Article
New hydrophobic interaction chromatography (HIC) handbook
Hydrophobic interaction chromatography (HIC) separates biomolecules under mild conditions according to differences in molecular hydrophobicity. HIC is often used as a next step to purify prote…
Article
Strategies and Emerging Technologies for mAb Capture
View this on-demand webcast >>
In this webinar, we will describe and evaluate different process intensification strategies for the monoclonal antibody (mAb) capture step. Strategies wi…
Article
Eliminating Residual Impurities Starts with a Strategic Plan
Eliminating Residual Impurities Starts with a Strategic Plan
Identifying the source, assessing the risk, and removing residual impurities requires a strategic approach.
By Cynthia A. Ch…
Article
Gene Therapies Push Viral Vector Production
Gene Therapies Push Viral Vector Production
Viral vectors show promise as a delivery mechanism for gene therapy, but which virus types are commercially viable?
By Feliza Miraso…